HOME > ARCHIVE
ARCHIVE
- Fujisawa Licenses GPCR Drug Target from TaiGen
March 3, 2003
- Shionogi Expects Sharp Recovery from FY2003
March 3, 2003
- Kaken to Codevelop Antifungals with Elitra of the US
March 3, 2003
- NBI's AII Receptor Antagonist Micardis Off to Strong Start
March 3, 2003
- Global CRO Market Grew to US$7 Billion in 2001: 6th Nomura Bioconference
March 3, 2003
- Dainippon Introduces New System to Boost R&D Efficiency
March 3, 2003
- PERSS SEMINAR
March 3, 2003
- Santen's New Mid-term Plan Focuses on Profits, Stronger R&D
March 3, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 3, 2003
- Prices Settled for 96% of Customers by Year-end: Suzuken
March 3, 2003
- Anthelios XL Sunscreen to Protect against UV Radiation: L'oreal Seminar
March 3, 2003
- End-of-year Price Agreement Rate Up 15-20% vs FY2000: Azwell
March 3, 2003
- DIAGNOSTIC NEWS IN BRIEF
March 3, 2003
- Intellectual Property Rights Must Be Considered Together with NHI Price System: FPMAJ President
March 3, 2003
- DIAGNOSTIC NEWS IN BRIEF
February 24, 2003
- Small, Mid-sized Makers Should Focus on Improved Drugs: Mr Seko of PMSRL
February 24, 2003
- REGULATORY NEWS IN BRIEF
February 24, 2003
- Mochida to Complete Self-supporting System by Splitting Off Its Core Businesses
February 24, 2003
- Iressa Expert Committee Issues Interim Report
February 24, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIE
February 24, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
